I’m sorry shell, but how does allogenic vs autologous CAR-T cells impact whether we attack the multitude of antigens expressed form AML? Isn’t the idea of Omnicar, that we can choose multiple different binders and administer that to the patient, regardless if the CAR-T cell is auto or allo?
It doesn’t make sense to me that we have scrapped the collaboration unless we plan to put the AML trial on the back burner. Perhaps this means we are going to pursue one of our solid tumour targets as our first in human trial. If we can make a dent in solid tumours with our CAR-T therapy that will well and truly put us on the worlds radar.
- Forums
- ASX - By Stock
- Ann: June 2023 Quarterly Update and Appendix 4C
I’m sorry shell, but how does allogenic vs autologous CAR-T...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.82M |
Open | High | Low | Value | Volume |
4.2¢ | 4.2¢ | 4.2¢ | $17.55K | 418.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 80471 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 225514 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 32852 | 0.042 |
3 | 1034391 | 0.041 |
9 | 797493 | 0.040 |
5 | 389000 | 0.039 |
2 | 225000 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 197849 | 1 |
0.045 | 831675 | 6 |
0.047 | 525000 | 2 |
0.048 | 58027 | 1 |
0.050 | 310539 | 3 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |